MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/13/2026

1. CRWV
2. SMCI
3. GAMI
4. LITE
5. SPY
6. ONON
7. CAVA
8. CSCO
9. NTHI
10. ETOR

Go back to MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
(NASDAQ: INKT) Delayed: 11.36 +0.13 (1.16%)
Previous Close $11.23    52 Week High $ 
Open $11.06    52 Week Low $ 
Day High $11.60    P/E N/A 
Day Low $11.06    EPS $ 
Volume 4,718